论文部分内容阅读
目的对血清癌胚抗原(CA)125测定在卵巢癌诊断中的价值进行评价。方法参照诊断性试验的评价指标,对文献的设计方案、研究对象的选择、参考值的确立、诊断试验的评价指标等进行评价。结果纳入的63篇文献中有62篇与金标准进行了比较,但未提及是否采用盲法;所提供的诊断性指标(敏感度、特异度、似然比等)不全面,对偏倚的控制没有描述,对采用同一种方法测定的研究文献,其所得结论不完全相同。结论提示目前尚无临床证据表明CA125可作为诊断卵巢癌的独立指标。
Objective To evaluate the value of serum carcinoembryonic antigen (CA) 125 in the diagnosis of ovarian cancer. Methods With reference to the evaluation indexes of diagnostic tests, the design of the literature, the selection of research objects, the establishment of reference values and the evaluation indexes of diagnostic tests were evaluated. Results Sixty-two of the 63 articles included were compared with the gold standard, but no mention was made of whether blindness was used or not; the diagnostic indicators provided (sensitivity, specificity, likelihood ratio, etc.) were not comprehensive, Control is not described, the conclusions obtained by the same method of determination of the research literature, not exactly the same. Conclusions suggest that there is no clinical evidence that CA125 can be used as an independent indicator of ovarian cancer diagnosis.